Navigation Links
Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma
Date:4/13/2009

linical efficacy with PCI-32765 in these disease models," said Dr. Mark Genovese, Professor of Medicine and Co-Chief of the Division of Immunology and Rheumatology at Stanford University Medical Center and member of Pharmacyclics' Scientific Advisory Board.

"Despite recent success with biologics in the treatment of B-cell NHL, there is still a large group of patients that do not respond to therapy or who experience recurrence," said Ranjana Advani, MD, Associate Professor, Stanford University Medical Center and principle investigator of the Phase 1 clinical trial. "A drug that could not only have an impact on this patient group, but also be delivered orally would represent a significant step forward in the treatment of this disease."

This Phase 1 study is evaluating the safety and pharmacokinetics of PCI-32765 in patients with refractory B-cell non-Hodgkin's lymphoma at Stanford University, MD Anderson Cancer Center and the University of Chicago using a 28-day dose-escalation design. The study is also utilizing a proprietary pharmacodynamic assay developed by Pharmacyclics to directly assess Btk drug occupancy. Preliminary results from the Phase I trial shows good patient tolerability under conditions of Btk-drug occupancy with potent bioactivity in targeted cell populations derived from the B-cell lymphoma patients.

Pharmacyclics Btk Presentations at AACR

Monday April 20, 2009

9:30 am - 1:00 pm; Minisymposium Novel Molecular Targets / Targeting Cell Death Pathways; Experimental and Molecular Therapeutics 12 Room 405-407, Colorado Convention Center 9:40am-9:55am

#1984 Btk is a Novel Therapeutic Target to Treat Large B-cell Lymphomas Ryan M. Young, Ashley Smith, Lee Honigberg, Yosef Refaeli. National Jewish Health, Denver, CO, Pharmacyclics, Inc., Sunnyvale, CA

Tuesday April 21, 2009

'/>"/>
SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
2. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
3. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
6. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
7. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
8. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
9. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
10. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
11. Aerovance Initiates Phase IIb Clinical Trial with Aerovant(TM) for the Treatment of Uncontrolled Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... PALO ALTO, Calif. , Dec, 22, 2014 ... of a Phase 2a study of lonafarnib in ...  The study was conducted at the National Institutes ... Bethesda, Maryland .  The double-blinded, randomized, placebo-controlled, ... 100 mg twice daily and 200 mg twice ...
(Date:12/22/2014)... TWi Biotechnology, Inc., today announced that ... TWi Biotechnology,s lead drug candidate, from The State ... for patent application numbered 201180018154.8.  This patent ... metabolite for treatment of type II diabetes.  The ... AC-201 for type II diabetes, and provides a ...
(Date:12/19/2014)...  Newport Corporation (NASDAQ: NEWP ) ... the company,s Board of Directors.  Dr. Kadia is ... of Evans Analytical Group, a leading global provider ... to companies in a wide range of industries.   ... Group, Dr. Kadia spent nine years with Life ...
Breaking Medicine Technology:Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2
... 2010 CareFusion (NYSE: ... today launched the EnVe™ ventilator , a ... 70-80 pounds lighter than other ventilators with similar ... The EnVe ventilator has the capability to ...
... Dec. 20, 2010 Codexis, Inc. (Nasdaq: CDXS ... Jaffray Clean Technology & Renewables Conference, to be held in ... be made by Robert Lawson, Senior Vice President and Chief ... noon Eastern Time.  A webcast and replay will be available ...
Cached Medicine Technology:CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 2CareFusion Launches EnVe Ventilator, Weighing 10 Times Less Than Traditional Critical Care Ventilators 3
(Date:12/24/2014)... Dr. Ronald Receveur, a New ... dental implants in a day, has written ... overusing teeth-whitening treatments. , In his blog published ... Receveur writes that overusing teeth-whitening treatments can lead to ... enamel. , “Because teeth-whitening treatments are available ...
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/22/2014)... December 22, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Medical Center in Oceanside, Calif. The top ... E. Smith has recently placed more than 900 healthcare ... a community owned, 397-bed, Gold Seal-approved, full-service acute-care hospital ...
(Date:12/22/2014)... 22, 2014 Sagacious Consultants, the premier ... subscription option to their ad hoc report writing service ... Customers can sign up for an annual subscription and ... month at a deeply discounted hourly rate. , ... has a progressively discounted rate. Subscription hours are contracted ...
(Date:12/22/2014)... News) -- U.S. and state health officials are investigating ... killed at least four people and sickened 28 others ... commercially produced, prepackaged caramel apples until more information becomes ... said in a news release. As of Dec. ... with the outbreak strains of the bacteria Listeria ...
Breaking Medicine News(10 mins):Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 2Health News:Tri-City Medical Center Retains B. E. Smith to Recruit New Chief Compliance Officer 3Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 2Health News:Sagacious Consultants’ New Subscription Packages Offer Customers Additional Report Writing Options 3Health News:CDC Warns of Listeria Danger From Caramel Apples 2
... Education Secretary,Gerald L. Zahorchak today issued the ... approving House Bill 1841, legislation to create,a statewide ... House Education Committee took a major step today ... care for educators,and cut down on teacher strikes," ...
... million Americans have survived a heart attack or have ... one cause of death in the United States. In ... diet and exercise, are known to reduce the risk ... proportion of heart attack survivors do not follow their ...
... Helps Drive Growth in ... Interactive Patient Care, ... of Interactive Patient Care (IPC) solutions, today announced that,Irwin Studen ... chief financial officer. With extensive experience in the,healthcare and technology ...
... back vivid, 30-year-old memories for patient, researchers say , , ... (DBS) may help improve memory, suggests a Canadian study ... prompted detailed memories in a patient. , DBS ... -- is used to treat Parkinson,s disease and other ...
... doctors as a hormone that boosts red-blood-cell production. Now, ... ophthalmologist at Children,s Hospital Boston, shows it also keeps blood ... not only add a new function to the hormone, but ... to patients with diseases affected by abnormal blood-vessel growth, such ...
... Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) announced today ... mg (Pantoprazole Sodium,DR), which is AB-rated to Wyeth,s ... Ltd. (Sun Pharma). Sun Pharma recently received,approval from ... its Abbreviated,New Drug Application (ANDA) for generic Protonix(R), ...
Cached Medicine News:Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 2Health News:UMass Medical School study finds patients diagnosed with coronary heart disease continue poor diets 3Health News:Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer 2Health News:Irwin Studen Joins GetWellNetwork as Senior Vice President and Chief Financial Officer 3Health News:Deep Brain Stimulation May Improve Recall 2Health News:Anemia treatment may be a double-edged sword 2Health News:Anemia treatment may be a double-edged sword 3Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 2Health News:Caraco Pharmaceutical Laboratories Ltd. to Market Generic Protonix(R) 3
For the quantitative determination of total cholesterol in serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... new dedicated high performance bio imaging system ... process of imaging chemiluminescent samples. It provides ... to use, thanks to new, unique image ... on the standard Genegnome, the Genegnome HR ...
Medicine Products: